Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate.
As the cancer with the highest morbidity and mortality rate in the world, the progress and approval of new lung cancer drugs have shown a blowout state in the past two years.
Especially in the field of lung cancer, targeted therapy drugs targeting specific mutated genes (such as EGFR, ALK, ROS1, MET, RET, NTRK, KRAS targeted therapy) have further improved the survival hope of many lung cancer patients.
At the American Society of Clinical Oncology Annual Meeting (ASCO) held in June 2019, the data of Repotrectinib (TPX-0005), a new targeted drug that swept across the three targets of ALK/ROS1/NTRK, was amazing.
Repotrectinib is a new generation of oral multi-targeted drug developed by Turning Point Therapeutics in the United States. It has inhibitory effects on ALK, ROS1 and NTRK. It can overcome a variety of gene mutations that are resistant to other TKIs and kill ROS1. , NTRK and ALK positive solid tumors.
The FDA granted priority approval to repotrectinib, which is expected to be on the market by the end of 2023!
According to “Onclive”, on May 30, FDA granted Repotrectinib a priority review qualification for the treatment of ROS1-positive locally advanced or patients with metastatic non-small cell lung cancer.
This qualification is based on the results of the phase I/II TRIDENT-1 trial, and Ribotinib will be approved before November 27, 2023 if it goes well .
It is worth mentioning that if the progress goes well this time, this drug is expected to be approved for marketing in China and the United States in the second half of this year, which will also become the “pioneer” among the second-generation NTRK/ROS1 inhibitors.
Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
